---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-127517"
form_type: "8-K"
ticker: null
cik: "0001772028"
company_name: "Scopus BioPharma Inc."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:28:29.980474+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Scopus BioPharma receives Nasdaq delisting notice; trading suspended Dec 19

## Summary
- Nasdaq Panel determined to delist SCPS after company failed to meet compliance milestones, including a specified financing transaction.
- Nasdaq trading will be suspended effective at the open on December 19, 2022.
- Company expects to trade on OTC Markets under same ticker SCPS; has applied for the OTCQB Venture Market.
- No assurance OTCQB application will be approved or that company can satisfy ongoing reporting requirements.

## SEC filing metadata
- accession: 0001104659-22-127517
- form_type: 8-K
- cik: 0001772028
- company_name: Scopus BioPharma Inc.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1772028/000110465922127517/0001104659-22-127517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1772028/000110465922127517/tm2232869d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-127517
- JSON: https://secwatch.observer/filing/0001104659-22-127517.json
- Plain text: https://secwatch.observer/filing/0001104659-22-127517.txt

## Key facts
- Listing & Compliance Notices
  Scopus BioPharma Inc. received a nasdaq delisting notice notice.
  - Exchange: nasdaq
  - Notice: delisting notice
  source text: December 15, 2022, of its determination to delist the Company’s common stock from Nasdaq. Such letter further informed the Company that Nasdaq will complete the delisting after, among other things, the lapsing of applicable appeal periods and that trading of the Company’s common stock on Nasdaq will be suspended effective at the open of trading on December 19, 2022. The Company anticipates that, upon suspension of trading on Nasdaq, its common stock will commence trading on one of the markets operated by the OTC Markets Group under its existing ticker symbol “SCPS”. The Company has submitted a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1772028/000110465922127517/0001104659-22-127517-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.